Every 8-K that Bio Green Med Solution, Inc. (BGMS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BGMS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BGMS filings page.
Bio Green Med Solution, Inc. reported second quarter results for the three months ended June 30, 2026, reflecting its transition into fire safety protection and distribution following the September 2025 acquisition of Fitters Sdn. Bhd. Product revenue from fire safety equipment was $336,000, generating a gross margin of approximately 23%.
Net loss was $0.4 million, improving from $1.3 million in the same period of 2025, driven largely by a sharp reduction in general and administrative expenses to $0.5 million from $1.2 million. There was no activity from discontinued biopharmaceutical operations in the current period.
Cash and cash equivalents totaled $3.8 million as of June 30, 2026, compared with $3.5 million at December 31, 2025, and the company estimates its current cash resources will fund planned expenditure into the first quarter of 2027. Total assets were $7.9 million and stockholders’ equity was $7.2 million, with liabilities remaining relatively low.
Bio Green Med Solution, Inc. announced that its board of directors declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock. The dividend will be paid on August 1, 2026 to preferred stockholders of record at the close of business on July 23, 2026.
Bio Green Med Solution, Inc. reported results from its 2026 annual shareholder meeting. Stockholders elected Class I directors Dr. Satis Waran Nair Krishnan and Inigo Angel Laurduraj to new three-year terms expiring at the 2029 annual meeting. Shareholders also ratified SFAI Malaysia Plt. (PCAOB: 7167) as independent auditors for the fiscal year ending December 31, 2026, and approved on an advisory basis the compensation of the company’s named executive officers and directors. Voting support for directors, auditors, and pay was high, with minimal opposition or abstentions.
Bio Green Med Solution, Inc. entered into a Securities Purchase Agreement with foreign accredited investors to sell 1,103,338 shares of common stock at $0.72 per share, raising aggregate gross proceeds of $794,403. The closing occurred on June 10, 2026, and the company plans to use the cash for general corporate and operating purposes.
At the same time, the company signed a Registration Rights Agreement requiring it to file and maintain an effective resale registration statement so investors can later resell these shares under the Securities Act or Rule 144. The shares were issued without registration under Regulation S to non‑U.S. persons.
Bio Green Med Solution, Inc. entered into a Business Combination Agreement to acquire Future NRG Sdn. Bhd. in an all‑stock share exchange. Future NRG will become a wholly owned subsidiary, while its selling shareholders are expected to own more than 99% of the combined company, leaving pre‑transaction Bio Green Med holders with less than 1%.
The deal aims to build a next‑generation environmental platform by combining Bio Green Med’s fire safety equipment business with Future NRG’s medical waste‑to‑energy operations in Malaysia. Closing requires shareholder approvals, Nasdaq listing approval for new shares, effectiveness of a Form S‑4 registration statement and other customary conditions, and may be terminated if not completed by December 31, 2026.
Bio Green Med Solution, Inc. reported first quarter 2026 results showing its transition into fire safety operations gaining traction but still producing a small loss. Product revenue from fire safety equipment reached $0.8 million for the three months ended March 31, 2026, with cost of sales of $0.6 million, reflecting an early revenue base in the new business.
General and administrative expenses fell sharply to $0.4 million from $4.2 million a year earlier, mainly as one-time change-of-control costs rolled off and management focused on tighter cost control. The company recorded a net loss of $0.2 million, similar to the prior-year loss from continuing and discontinued operations combined.
Cash and cash equivalents were $3.3 million as of March 31, 2026, and Bio Green Med estimates these resources will fund planned expenditures into the fourth quarter of 2026. During the quarter, its 6% Convertible Exchangeable Preferred Stock was delisted from Nasdaq, although the common stock remains listed, and holders of the preferred received a $0.15 per-share quarterly cash dividend paid on May 1, 2026.
Bio Green Med Solution, Inc. announced that its Board of Directors declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock. The dividend will be paid on May 1, 2026 to preferred stockholders of record at the close of business on April 23, 2026.
Bio Green Med Solution, Inc. reported its first fire-safety product revenue after shifting away from biopharmaceuticals. For 2025, product revenue from fire safety equipment was $0.7 million, while net loss narrowed sharply to $3.0 million from $11.2 million in 2024.
Cash and cash equivalents were $3.5 million as of December 31, 2025, and the company expects existing cash to fund operations into the third quarter of 2026. Results reflect the September 2025 acquisition of Fitters Sdn. Bhd., liquidation of the U.K. subsidiary, and sale of the Plogosertib drug asset, which together produced a $4.9 million gain on deconsolidation and $0.3 million from the asset sale.
R&D expenses fell to $0.8 million for 2025 from $6.7 million in 2024 as legacy drug programs wound down, while general and administrative costs rose to $7.7 million due to one-time change-of-control expenses. A quarterly dividend of $0.15 per share was paid on the 6% Convertible Exchangeable Preferred Stock, and a warrant exchange triggered a large deemed dividend of $11.0 million to common shareholders.
Bio Green Med Solution, Inc. reports that Nasdaq will delist its 6% Convertible Exchangeable Preferred Stock (symbol BGMSP) after the security failed to regain compliance with the $1 million minimum market value of publicly held shares requirement by March 10, 2026. Nasdaq notified the company on March 12, 2026, that trading in the preferred shares is expected to be suspended at the opening of business on March 23, 2026, with delisting expected on or after April 2, 2026. The company does not plan to appeal and believes the preferred stock may be quoted and traded on the OTC Markets after delisting. The company states that this action does not affect its common stock, which continues to trade on the Nasdaq Capital Market under the symbol BGMS.
Bio Green Med Solution, Inc. reported that its board declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock.
The dividend will be paid on February 1, 2026 to holders of the preferred stock who are on record as of the close of business on January 22, 2026. This action provides ongoing cash distributions specifically to investors holding the company’s preferred stock class.
Bio Green Med Solution, Inc. furnished a Form 8-K announcing it issued a press release with its third quarter 2025 results. The disclosure was furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).
The press release is attached as Exhibit 99.1 and dated November 13, 2025. The company’s securities are listed on the Nasdaq Capital Market under BGMS (common) and BGMSP (preferred).